BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $105.00 Price Target at Jefferies Financial Group

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by equities researchers at Jefferies Financial Group from $104.00 to $105.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 59.62% from the stock’s current price.

A number of other research firms have also recently weighed in on BMRN. Piper Sandler boosted their target price on shares of BioMarin Pharmaceutical from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. UBS Group set a $88.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday. HC Wainwright upped their price objective on BioMarin Pharmaceutical from $59.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday. Finally, Citigroup increased their price objective on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN traded up $1.11 during trading on Monday, reaching $65.78. The company’s stock had a trading volume of 795,224 shares, compared to its average volume of 2,061,290. The firm has a market cap of $12.73 billion, a price-to-earnings ratio of 177.78, a price-to-earnings-growth ratio of 0.46 and a beta of 0.24. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm has a 50 day moving average of $61.70 and a 200-day moving average of $58.15. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts expect that BioMarin Pharmaceutical will post 4.1 EPS for the current fiscal year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several large investors have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $66,107,000. Rice Hall James & Associates LLC bought a new position in shares of BioMarin Pharmaceutical in the 2nd quarter worth $14,203,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at $39,312,000. Swedbank AB raised its position in BioMarin Pharmaceutical by 70.6% during the fourth quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock valued at $47,350,000 after purchasing an additional 329,794 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $2,804,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.